Published within
|«
«
|
...
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Shire has announced a deal with GlaxoSmithKline to co-promote the ADHD treatment Vyvanse in the US. Shire's successful marketing of the leading blockbuster brand, Adderall XR, in the absence of such a partner may indicate that GlaxoSmithKline's contribution will be both marginal and too late, coming as it does after the launch of generic versions of Adderall XR.
Published By Datamonitor
|
01 Apr 2009 |
|
CommentWire
|
Shire Pharmaceuticals has settled a crucial patent case with US generics company Barr Laboratories regarding its ADHD drug Adderall XR. The agreement will prove vital to Shire, minimizing the generic threat and giving the company time to move patients over to its late-stage pipeline ADHD drug, NRP 104, should it gain approval.
Published By Datamonitor
|
16 Aug 2006 |
|
CommentWire
|
The FDA approval of ulcerative colitis drug Lialda is positive news for a trio of companies: Shire, Giuliani and Cosmo SpA. Lialda's minimum once daily dosage regime is a significant step forward for ulcerative colitis treatment which should lead to strong sales in the indication, with some additional revenue generated from off-label sales for the treatment of other lower GI tract conditions.
Published By Datamonitor
|
19 Jan 2007 |
|
CommentWire
|
The main driver of this Shire's plan to acquire New River is Vyvanse, New River Pharmaceutical's new ADHD drug and potential follow up to Shire's Adderall XR, which is estimated to expire in 2009. If Vyvanse can live up to its potential, the deal will ensure that Shire maintains its market leading position in the ADHD treatment sector.
Published By Datamonitor
|
21 Feb 2007 |
|
CommentWire
|
Following trials of their methylphenidate transdermal system (MTS), which is in development for the treatment of attention deficit hyperactivity disorder (ADHD) in children, Noven and Shire have announced positive preliminary results. The drug should launch in the US by the end of 2006, and has the potential to become the market leading ADHD stimulant by 2010.
Published By Datamonitor
|
07 Apr 2005 |
|
CommentWire
|
Pooled analysis of four major studies of Valdoxan has shown significantly greater efficacy and an increased percentage of responders than conventional depression treatments. Due to its novel mechanism of action, strong efficacy profile, increased tolerability and potential to alleviate comorbid sleep disturbances, Valdoxan is well positioned to become a leading treatment in the depression market.
Published By Datamonitor
|
03 Sep 2010 |
|
CommentWire
|
The regulator's decision to break the orphan drug status of Biogen's Avonex and allow Rebif's US sale is a massive boost to Serono's growth prospects. The resulting extra revenues should allow Serono to increase its comparatively weak pipeline through in-licensing deals - and also by going on the acquisition trail.
Published By Datamonitor
|
13 Mar 2002 |
|
CommentWire
|
Strong sales for multiple sclerosis drug Rebif have failed to prevent a fall in Q3 profits for Swiss biotech firm Serono. Having already been hit by settlement charges related to its HIV treatment Serostim earlier this year, and given the company's relatively weak pipeline, it is now crucial that Serono looks to the effective use of its financial resources in order to ensure a profitable future.
Published By Datamonitor
|
26 Oct 2005 |
|
CommentWire
|
The addition of safinamide to Serono's late stage R&D pipeline will fill the gap left by Merck KGaA's halted Parkinson's disease (PD) product, sarizotan, when the two companies merge to form Merck-Serono Biopharmaceuticals. However, the drug is not expected to have a large impact on the PD market and thus will not be a key growth driver for the company.
Published By Datamonitor
|
18 Oct 2006 |
|
CommentWire
|
Serono has announced data from an ongoing two year Phase IIIb trial demonstrating that the new formulation of multiple sclerosis drug Rebif offers improvement in tolerability and immunogenicity profiles. Although, if launched, the drug is expected to lead to improved compliance, long term uptake will be threatened by the development of oral formulation drugs.
Published By Datamonitor
|
29 Sep 2006 |
|
|«
«
|
...
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.